J. Jay Cho Ph.D.

J. Jay Cho Ph.D.

Patterson Belknap Webb & Tyler LLP

Contact
View Bio
RSS

Latest Posts › BPCI

Share:

FDA’s Draft Guidance for Industry Seeks to Answer Questions on Biosimilar Interchangeability

FDA has published new draft guidance for industry titled “Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act.” ...more

11/30/2020  /  Biologics , Biosimilars , BPCI , Draft Guidance , Food and Drug Administration (FDA) , Pharmaceutical Industry , Public Health Service Act
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide